Abstract
Abstract
Background
Many non-COVID-19 trials were disrupted in 2020 and either struggled to recruit participants or stopped recruiting altogether. In December 2019, just before the pandemic, we were awarded a grant to conduct a randomised controlled trial, the Should I Take Aspirin? (SITA) trial, in Victoria, the Australian state most heavily affected by COVID-19 during 2020.
Main body
We originally modelled the SITA trial recruitment method on previous trials where participants were approached and recruited in general practice waiting rooms. COVID-19 changed the way general practices worked, with a significant increase in telehealth consultations and restrictions on in person waiting room attendance. This prompted us to adapt our recruitment methods to this new environment to reduce potential risk to participants and staff, whilst minimising any recruitment bias. We designed a novel teletrial model, which involved calling participants prior to their general practitioner appointments to check their eligibility. We delivered the trial both virtually and face-to-face with similar overall recruitment rates to our previous studies.
Conclusion
We developed an effective teletrial model which allowed us to complete recruitment at a high rate. The teletrial model is now being used in our other primary care trials as we continue to face the impacts of the COVID-19 pandemic.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Medicine (miscellaneous)
Reference18 articles.
1. Trends, Charts, and Maps - ClinicalTrials.gov [Internet]. [cited 2021 May 28]. Available from: https://clinicaltrials.gov/ct2/resources/trends.
2. van Dorn A. COVID-19 and readjusting clinical trials [Internet]. Lancet (London, England). 2020;396:523–4 NLM (Medline). [cited 2021 May 28].. Available from: https://www.fda.gov/.
3. Milton S, McIntosh J, Macrae F, Chondros P, Trevena L, Jenkins M, et al. An RCT of a decision aid to support informed choices about taking aspirin to prevent colorectal cancer and other chronic diseases: a study protocol for the SITA (Should I Take Aspirin?) trial. Trials 2021 221. 2021;22(1):1–17 [cited 2021 Aug 11]. Available from: https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-021-05365-8.
4. Caly L, Druce J, Roberts J, Bond K, Tran T, Kostecki R, et al. Isolation and rapid sharing of the 2019 novel coronavirus (SARS-CoV-2) from the first patient diagnosed with COVID-19 in Australia. Med J Aust. 2020;212(10):459–62 [cited 2020 Sep 15]. Available from: https://onlinelibrary.wiley.com/doi/abs/10.5694/mja2.50569.
5. Department of Health and Human Services Victoria | Victorian coronavirus (COVID-19) data [Internet]. [cited 2021 Jun 9]. Available from: https://www.dhhs.vic.gov.au/victorian-coronavirus-covid-19-data.
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献